Z1P in the news
Z1P in the news
April 2015
ZoneOne Pharma awarded NCI grant to retarget FDA-approved anticancer liposomal drugs to cancer stem cells.
Project number: 1R41CA192689-01
March 2015
ZoneOne Pharma awarded phase II NIH grant for twice weekly subcutaneous liposome chelator to treat transfusional iron overload.
Project number: 2R44HD075429-02
September 2014
ZoneOne Pharma awarded FDA grant to develop evaluation of in vitro release methods for liposomal amphotericin B.
Project number: 1U01FD005249-01
September 2014
ZoneOne Pharma awarded FDA grant for the development of a liposome doxorubicin drug product release assay.
Project number: 3U01FD004893-01S1
July 2013
ZoneOne Pharma awarded phase 1 FDA grant for twice weekly subcutaneous liposome chelator to treat transfusional iron overload.
Project number: 1R43HD075429-01
September 2012
ZoneOne Pharma awarded an National Cancer Institute contract to develop a liposomal Hsp90 inhibitor for cancer treatment
Project number: N43CO120082
Events & Presentations
December 2016
The American Society of Hematology (ASH) 58th annual meeting
San Diego, CA
June 30th-July 02, 2016
9th World Drug Delivery Summit, New Orleans, Louisiana
Dr. Noble will give an oral presentation on the L-DFO project entitled "Liposome Encapsulated Deferoxamine is a More Effective Iron Chelator than Desferal® in an Iron Overloaded Mouse Model"